Patents Represented by Attorney Richard Aron Osman
-
Patent number: 7193034Abstract: The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise ?-amine protected 4,5-dehydroleucine or ?-amine protected (2S)-aminolevulinic acid and/or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.Type: GrantFiled: September 6, 2005Date of Patent: March 20, 2007Assignee: Regents of the University of CaliforniaInventor: Carolyn R. Bertozzi
-
Patent number: 7192714Abstract: The invention provides methods and compositions for modeling and detecting LDL receptor transmembrane signaling by detecting proteolysis of an LDL receptor transmembrane domain. The method comprises the steps of: a) providing a sample comprising a cell membrane comprising (i) a polypeptide comprising an LDL receptor transmembrane domain fused to a C-terminal tail, and (ii) a protease which specifically cleaves the domain and thereby releases the tail from the membrane; b) incubating the sample under conditions wherein the protease cleaves the domain and thereby releases the tail from the membrane; and c) detecting a resultant released tail.Type: GrantFiled: October 12, 2001Date of Patent: March 20, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Petra May
-
Patent number: 7179618Abstract: Streptavidin-metallothionein chimeric proteins with biological recognition specificity in which the streptavidin moiety provides high affinity biotin binding and the metallothionein moiety provides a high affinity metal binding. The binding affinity of the streptavidin-metallothionein chimeric protein both for biotin and heavy metal ions allows specific incorporation into, conjugation with, or labelling of any biological material containing biotin with various heavy metal ions.Type: GrantFiled: November 1, 2002Date of Patent: February 20, 2007Assignee: Regents of the University of CaliforniaInventors: Takeshi Sano, Alexander N. Glazer, Charles R. Cantor
-
Patent number: 7176000Abstract: The invention provides multifunctional fusion constructs which are rapidly incorporated into a macromolecular structure such as a phycobilisome such that the fusion proteins are separated from one another and unable to self-associate. The invention provides methods and compositions for displaying a functional polypeptide domain on an oligomeric phycobiliprotein. including fusion proteins comprising a functional displayed domain and a functional phycobiliprotein domain incorporated in a functional oligomeric phycobiliprotein. The fusion proteins provide novel specific labeling reagents.Type: GrantFiled: July 10, 2003Date of Patent: February 13, 2007Assignee: Regents of the University of CaliforniaInventors: Alexander N. Glazer, Yuping Cai
-
Patent number: 7172862Abstract: Agents that modulate an interaction of an FBL2 protein with an NS5A or NS5B Flaviviridae protein in a mixture are identified by contacting the mixture with a candidate agent under conditions wherein but for the presence of the agent, the FBL2 protein and the Flaviviridae protein engage in a reference interaction; and detecting an agent-biased interaction. Flaviviridae replication is inhibited by contacting a Flaviviridae-infected cell with an FBL2-specific reagent; and detecting a resultant Flaviviridae replication inhibition.Type: GrantFiled: May 4, 2005Date of Patent: February 6, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Michael J. Gale, Jr., Michael S. Brown, Joseph L. Goldstein, Chunfu Wang, Jin Ye
-
Patent number: 7148332Abstract: High affinity monoclonal antibodies for recognizing estrogen receptor (clone SP1) with immunohistochemistry and methods for creating such an antibody are disclosed. The lagomorph derived ER antibody provides a significant advantage over the currently available mouse ER antibodies in that there is no need for target retrieval when performing immunohistochemistry. Furthermore, the very low background when the lagomorph derived ER antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new ER (clone SP1) antibody had favorable results when compared to mouse monoclonal ER antibodies (clone 1D5). The lagomorph derived ER antibody may prove of great value in the assessment of ER status in human breast cancer. Humanized versions of the ER antibody may also provide therapeutic benefits.Type: GrantFiled: September 11, 2002Date of Patent: December 12, 2006Assignee: Spring BioscienceInventors: Haiying Xia, Zhida Huang
-
Patent number: 7149631Abstract: Computational methods identify alternate splice forms of known gene transcripts and isoforms that are subject to NMD (nonsense-mediated decay). These methods were used to identify thousands of human genes that generate alternative splice forms, and to demonstrate that about a third of these are subject to NMD. This high prevalence of NMD-targeted transcripts indicates a systemic way of regulating gene expression—by shunting gene expression to nonproductive splice variants. This endemic regulation is exploited to engineer regulation of gene expression, to characterize splice pathway components and to assay splice environments, for example, using NMD-regulated reporter genes.Type: GrantFiled: May 31, 2002Date of Patent: December 12, 2006Assignee: Regents of the University of CaliforniaInventors: Steven E. Brenner, Richard E. Green, Benjamin P. Lewis
-
Patent number: 7144714Abstract: Methods for making siRNA comprise recombinantly coexpressing a Dicer protein with an R2D2 protein to form a complex comprising the R2D2 protein and the Dicer protein, and contacting the complex with a double-stranded (ds) RNA under conditions wherein the complex cleaves the dsRNA into siRNA. The R2D2 protein may be a Drosophila R2D2 protein and the Dicer protein may be a Drosophila Dicer-2 protein. The Dicer protein and the R2D2 protein may be coexpressed in insect cells, such as S2, Sf9 or Hi5 cells, using a baculovirus expression system.Type: GrantFiled: September 25, 2003Date of Patent: December 5, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Xiaodong Wang, Qinghua Liu
-
Patent number: 7138228Abstract: Post-translational O-sulfonation of a serine or threonine residue of proteins is detected, optionally comparatively, wherein the detected O-sulfonation is detected under a first physiological condition, and is compared with a control O-sulfonation detected under a second physiological condition, and a difference between the detected and control O-sulfonations indicates a difference between the first and second physiological conditions. Predetermined changes in physiological conditions are used to infer specific changes in O-sulfonation. Proteins are modified by introducing a predetermined change in O-sulfonation at a serine or threonine residue of the protein, and optionally, detecting a resultant change in O-sulfonation. These methods include introducing or increasing O-sulfonation, eliminating or reducing O-sulfonation; and derivatizing or substituting O-sulfonation.Type: GrantFiled: September 5, 2003Date of Patent: November 21, 2006Assignees: Regents of the University of California, Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Alma L. Burlingame, Katalin F. Medzihradszky, Zsuzsanna Darula, Eran Perlson, Michael Fainzilber, Robert J. Chalkley, Darren Tyson, Ralph A. Bradshaw
-
Patent number: 7132278Abstract: The invention provides methods and compositions relating to a novel kinase designated PAS Kinase (PASK). The compositions include isolated polypeptides comprising a native PASK protein or a PASK N-terminal domain and polypeptides consisting of a PASK PAS-A or PAS-B domain, as well as isolated polynucleotides encoding such polypeptides, and expression vectors and cells comprising such polynucleotides. The methods include binding assays comprising the steps of incubating a mixture comprising a subject polypeptide with a ligand under conditions wherein the polypeptide binds the ligand; and detecting binding of the polypeptide to the ligand.Type: GrantFiled: November 19, 2001Date of Patent: November 7, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Steven L. McKnight, Kevin Gardner, Shannon Harper, Jared Rutter, Carolyn Michnoff, Carlos Amezcua
-
Patent number: 7132454Abstract: Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding.Type: GrantFiled: August 27, 2004Date of Patent: November 7, 2006Assignee: Regents of the University of CaliforniaInventors: Qiang Zhou, Jasper H. N. Yik, Ruichuan Chen
-
Patent number: 7125687Abstract: The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for pen transcripts), therapy (e.g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e.g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc.).Type: GrantFiled: May 5, 2000Date of Patent: October 24, 2006Assignee: Exelixis, Inc.Inventors: Daniel Tim Curtis, George Ross Francis, Michael Christopher Ellis, David Andrew Ruddy, Sharmon Monique Nicoll, Garth Joseph McGrath
-
Patent number: 7115577Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: December 27, 2004Date of Patent: October 3, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Patent number: 7105313Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.Type: GrantFiled: February 13, 2003Date of Patent: September 12, 2006Assignee: Amgen Inc.Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne C. de la Brousse, Jin-Long Chen
-
Patent number: 7101681Abstract: Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.Type: GrantFiled: September 30, 1998Date of Patent: September 5, 2006Assignee: Amgen, Inc.Inventors: Kevin Lustig, Patrick Baeuerle, Holger Beckmann, Jin-Long Chen, Bei Shan
-
Patent number: 7094758Abstract: The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis.Type: GrantFiled: December 5, 2005Date of Patent: August 22, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Xiaodong Wang, Chunying Du
-
Patent number: 7087433Abstract: A method for altering transcription in a cell comprising an amount of active CDK9/cyclin, comprises the steps of: (a) introducing in the cell an agent which modulates the amount of active CDK9/cyclin in the cell, and thereby alters transcription in the cell, wherein the agent comprises an RNA selected from the group consisting of an RNA aptamer that specifically binds CDK9/cyclin, a CDK9/cyclin-binding domain of 7SK RNA, a 7SK RNA-binding antisense 7SK RNA domain, and a 7SK RNA-specific RNAi, and (b) detecting a resultant altering of transcription in the cell. Methods for screening for an agent which modulates 7SK RNA-CDK9/cyclin binding generally comprise the steps of (a) incubating a mixture of 7SK RNA, CDK9/cyclin and a candidate agent under conditions wherein but for the presence of the agent, the 7SK RNA and CDK9/cyclin engage in a reference binding; and (b) detecting an agent-biased binding of the 7SK RNA to the CDK9/cyclin.Type: GrantFiled: August 25, 2002Date of Patent: August 8, 2006Assignee: The Regents of the University of CaliforniaInventors: Qiang Zhou, Zhiyuan Yang, Qingwei Zhu, Kunxin Luo
-
Patent number: 7087369Abstract: Steinhardt defined medium preserves cornea tissue during cold storage. Tissue preservation kits comprise a premeasured amount of Steinhardt's medium and copackaged instructions describing use of the medium to preserve a tissue. Kits for making Steinhardt medium comprise premeasured amounts of medium ingredients; and copackaged instructions describing how to combine the ingredients to make the medium. The medium is made by combining the recited ingredients, and used by incubating a tissue in the medium.Type: GrantFiled: December 17, 2003Date of Patent: August 8, 2006Assignee: The Regents of the University of CaliforniaInventor: Richard A. Steinhardt
-
Patent number: 7065451Abstract: The invention relates to computer-based systems and methods for the design, comparison and analysis of genetic and proteomic databases. In a particular embodiment, the recited systems and methods have been implemented in a computer tool called ARROGANT. ARROGANT, in the analysis mode, is a comprehensive tool for providing annotation to large gene and protein collections. ARROGANT takes in a large collection of sequence identifiers and associates it with other information collected from many sources like sequence annotations, pathways, homology, polymorphisms, artifacts, etc. The simultaneous annotation for a large assembly of genes makes the collection of genomic/EST sequences truly informative.Type: GrantFiled: May 24, 2001Date of Patent: June 20, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Harold R. Garner, Amit Kulkarni
-
Patent number: 7056688Abstract: The invention provides methods and compositions for inducing and detecting signal transduction through LDL receptors, including specifically detecting a stress that alters a functional interaction of a low density lipoprotein (LDL) receptor binding polypeptide with an LDL receptor interaction domain, by (a) introducing a predetermined stress into a system which provides a physical interaction of an LDL receptor binding polypeptide with an LDL receptor intracellular binding polypeptide interaction domain, whereby the system provides a stress-biased interaction of the binding polypeptide and the interaction domain, wherein the absence of the stress, the system provides a unbiased interaction of the binding polypeptide and the interaction domain; and (b) detecting the stress-biased interaction of the binding polypeptide and the interaction domain, wherein the binding polypeptide is selected from SEMCAP-1, JIP-1, PSD-95, JIP-2, Talin, OMP25, CAPON, PIP4,5 kinase, Na channel brain 3, Mint1, ICAP-1 and APC subunitType: GrantFiled: August 1, 2002Date of Patent: June 6, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Joachim Herz, Michael Gotthardt